Provention Bio to Present at Two Upcoming Virtual Investor Conferences
March 03, 2022

RED BANK, N.J., March 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in two upcoming virtual investor conferences in March.

Ashleigh Palmer, Provention Bio's Chief Executive Officer and Co-Founder will participate in a company presentation at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8th, 2022, at 9:50 am EST. The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events.

Additionally, the company announced management will participate in a fireside chat presentation at the Oppenheimer & Co. 32nd Annual Healthcare Conference on Wednesday, March 16th, 2022, at 2:00 pm EST. The fireside chat will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events.

Both webcasts will be archived on the Company's website for 30 days following the presentation.

About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contacts:
Robert Doody
VP of Investor Relations
rdoody@proventionbio.com
484-639-7235

SOURCE Provention Bio, Inc.